Dornase Alfa is primarily indicated for which condition?

Dornase Alfa is primarily indicated for the management of cystic fibrosis, specifically for patients who experience thick, viscous mucus production. This enzyme works by hydrolyzing DNA in the mucus, which can help to reduce its viscosity and improve airway clearance. Patients with cystic fibrosis often suffer from the buildup of thick mucus in the lungs, leading to increased risk of infection and difficulty in breathing. By breaking down the DNA component of the mucus, Dornase Alfa helps facilitate better lung function and improves overall respiratory health in these patients.

The other conditions listed are not typically treated with Dornase Alfa. For instance, chronic obstructive pulmonary disease (COPD) and asthma exacerbations may require bronchodilators or corticosteroids, while pneumonia in elderly patients would necessitate different antibiotic treatments. Therefore, the focus on Dornase Alfa lies specifically with addressing the challenges faced by individuals suffering from cystic fibrosis.